Endocrine therapy is highly effective in treating prostate cancer, but there is a problem that long-term treatment must be adhered to, and long-term endocrine therapy is still the accepted protocol for prostate cancer treatment. Intermittent androgen blockade therapy means that after 6-9 months of hormone therapy, if the patient’s PSA level drops to the ideal state, all hormone therapy drugs are started to be discontinued so that the testosterone level in the patient’s body returns to the pre-treatment level, and then the next round of hormone therapy is started when the PSA level rises to a certain level. However, there is no unified opinion on which patients are suitable for intermittent hormone therapy, how long they can stop taking the medication, how long they can stop taking the medication, and to what extent the PSA level rises before they need to take the medication again, so up to now, intermittent endocrine therapy is only a clinical trial.